Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

lutetium zadavotide guraxetan (PNT2002)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Eli Lilly, Lantheus

Drug class:

Ionizing radiation emitter, PSMA inhibitor

Related drugs:

177 Lu-FC705 (0)

BAY 2315497 (0)

177Lu-satetraxetan-lilotomab (4)

ibritumomab tiuxetan (3)

Actinium-225 conjugated to daratumumab (2)

177Lu-DTPA-omburtamab (0)

177Lu-LNC1010 (0)

177Lu-P17-087 (0)

177Lu-P17-088 (0)

177Lu-PSMA-R2 (0)

iodine I 131 tositumomab (0)

samarium-153 DOTMP (0)

epratuzumab Y-90 (0)

rhenium Re186 obisbemeda (0)

lutetium-177 DOTA satoreotide (0)

67Cu MeCOSar octreotate (0)

lutetium Lu 177 vipivotide tetraxetan (4)

225Ac-FL-020 (1)

JNJ-63898081 (1)

177Lu-LNC1003 (0)

177 Lu-FC705 (0)

BAY 2315497 (0)

›

FOLH1 expression	Prostate Cancer	FOLH1 expression	Prostate Cancer	PNT2002 Sensitive: B - Late Trials PNT2002 Sensitive : B	PNT2002 Sensitive: B - Late Trials PNT2002 Sensitive : B
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	PNT2002 Sensitive: B - Late Trials PNT2002 Sensitive : B	PNT2002 Sensitive: B - Late Trials PNT2002 Sensitive : B